Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Chronic obstructive pulmonary disease

Triple therapy cuts exacerbations in COPD regardless of baseline reversibility

Research presented at the CHEST annual meeting shows that triple therapy with fluticasone furoate, umeclidinium and vilanterol reduces the number of moderate-to-severe exacerbations for people living with chronic obstructive pulmonary disease.

Triple therapy reduces the number of moderate-to-severe exacerbations in people with chronic obstructive pulmonary disease (COPD), regardless of whether their airway obstruction is bronchodilator-reversible, a study presented at the CHEST annual meeting (6–10 October 2018; San Antonio, Texas) has shown[1].

The 52-week trial involved 10,355 people with COPD with a history of moderate-to-severe exacerbations in the previous 12 months. They were randomly assigned to triple therapy with inhaled corticosteroid fluticasone furoate (FF)/long-acting muscarinic agonist (LAMA) umeclidinium (UMEC)/long-acting beta-agonist (LABA) vilanterol (VI) or dual therapy with FF/VI or UMEC/VI. Patients were tested at baseline for airway obstruction reversibility with salbutamol and defined as either reversible (18%) or non-reversible (82%). 

The researchers found that the rate of moderate-to-severe exacerbations was reduced by 40% in reversible patients and by 21% in non-reversible patients with triple therapy, compared with UMEC/VI dual therapy. Severe exacerbations were reduced by 44% and 31%, respectively.

Moderate-to-severe exacerbations were also significantly reduced compared with FF/VI in both reversible and non-reversible patients. Although, FF/UMEC/VI did not reduce the rate of severe exacerbations over FF/VI in reversible patients.

International guidelines recommend dual therapy (LABA/LAMA) for most patients with COPD, with the addition of inhaled corticosteroids only for those with frequent exacerbations. It was previously uncertain whether baseline reversibility, which indicates whether patients are bronchodilator-responsive, affects treatment response to triple therapy.

“Regardless of baseline reversibility, [triple therapy] showed statistically significant and clinically relevant improvements on a range of important outcomes,” the researchers concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205754

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.